Mentice AB
The answer first
Does Mentice beat the market?
Yes, Mentice has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 25% of Nordic stocks
- Quality4
- Value23
- Trend89
No. 119 of 195 in healthcare
Expectations in the price
Low expectations
For the share to return about 9% a year from today's price, the cash Mentice keeps must grow about 2% a year for 10 years.
Max for seven days
Follow Mentice with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Mentice
Your first answer is free, no account needed.
Do you own Mentice, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Mentice and a few more. Free, no card.
Super Stock+44.6%In short
- Mentice has risen 27.4% over the past year, including dividends.
- Overall, Mentice ranks better than 25% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 86.3%. The price is 90.8% below its peak now.
What do analysts think of Mentice?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 25% of Nordic stocks.
No. 119 of 195 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 192 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.20
- Asset turnoverSales divided by everything the company owns1.01
- Return on equityProfit divided by equity−16.8%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 89 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity4.2
- P/SPrice divided by sales1.5
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flow12.5
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 27 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+26.5%
- 6 months+10.4%
- 9 months+36.1%
- 12 months+27.4%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Mentice
One fund we follow owns Mentice. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Mentice
Mentice AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 130 employees.
Mentice AB (publ), together with its subsidiaries, develops, sells, and markets solutions for training and decision support in the clinical area of interventional angiography in cardiology, neurology, vascular surgery, and radiology. It operates through the Mentice VIST, Physical Sim, and Ankyras segments. The company offers virtual simulation products, including VR simulator platforms; procedural learning models; peripheral vascular; patient simulator accessories and extensions for endovascular therapies; and Angiosuite integrations, such as the VIST virtual patient and Laerdal SimMan vascular medical simulator.


See the full analysis of Mentice.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card